[Chronic Kidney Disease-a Cardiovascular High-risk Constellation]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2019 Oct 4

PMID 31578597

Authors

T Speer

S J Schunk

D Fliser

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is associated with substantial cardiovascular morbidity and mortality. This is mediated by the high prevalence of traditional cardiovascular risk factors in patients with CKD such as arterial hypertension and diabetes mellitus, but also by the presence of CKD-specific so-called nontraditional cardiovascular risk factors such as vascular calcification, uremic toxins, uremic dyslipidemia as well as inflammation and oxidative stress. Therefore, the primary and secondary prevention of cardiovascular disease represents an integral part of nephrology. This entails optimal control of blood pressure and diabetes, therapy of the uremic dyslipidemia as well as lifestyle-modifying factors such as weight reduction and smoking cessation.

References

Ali S, Dave N, Virani S, Navaneethan S . Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019; 21(9):32. DOI: 10.1007/s11883-019-0794-6. View

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View

Verbeke F, Lindley E, van Bortel L, Vanholder R, London G, Cochat P . A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with.... Nephrol Dial Transplant. 2013; 29(3):490-6. DOI: 10.1093/ndt/gft321. View

Palmer S, Craig J, Navaneethan S, Tonelli M, Pellegrini F, Strippoli G . Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 157(4):263-75. PMC: 3955032. DOI: 10.7326/0003-4819-157-4-201208210-00007. View

Gansevoort R, Correa-Rotter R, Hemmelgarn B, Jafar T, Lambers Heerspink H, Mann J . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382(9889):339-52. DOI: 10.1016/S0140-6736(13)60595-4. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Fried L, Emanuele N, Zhang J, Brophy M, Conner T, Duckworth W . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369(20):1892-903. DOI: 10.1056/NEJMoa1303154. View

Charytan D, Sabatine M, Pedersen T, Im K, Park J, Lira Pineda A . Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019; 73(23):2961-2970. DOI: 10.1016/j.jacc.2019.03.513. View

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

10.

Toth P, Dwyer J, Cannon C, Colhoun H, Rader D, Upadhyay A . Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018; 93(6):1397-1408. DOI: 10.1016/j.kint.2017.12.011. View

11.

Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F . SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008; 359(8):789-99. DOI: 10.1056/NEJMoa0801936. View

12.

Drueke T, Massy Z . Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010; 6(12):723-35. DOI: 10.1038/nrneph.2010.143. View

13.

Wanner C, Tonelli M . KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85(6):1303-9. DOI: 10.1038/ki.2014.31. View

14.

Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N . Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity. 2013; 38(4):754-68. DOI: 10.1016/j.immuni.2013.02.009. View

15.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

16.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W . Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2015; 67(5):728-41. DOI: 10.1053/j.ajkd.2015.10.011. View

17.

Zewinger S, Schumann T, Fliser D, Speer T . Innate immunity in CKD-associated vascular diseases. Nephrol Dial Transplant. 2015; 31(11):1813-1821. DOI: 10.1093/ndt/gfv358. View

18.

Catapano A, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H . 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39):2999-3058. DOI: 10.1093/eurheartj/ehw272. View

19.

Mann J, Orsted D, Brown-Frandsen K, Marso S, Poulter N, Rasmussen S . Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9):839-848. DOI: 10.1056/NEJMoa1616011. View

20.

Speer T, Owala F, Holy E, Zewinger S, Frenzel F, Stahli B . Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J. 2014; 35(43):3021-32. DOI: 10.1093/eurheartj/ehu111. View